SS-31 Study Explained: Elamipretide SS-31 and Nicotinamide Mononucleotide NMN Combination Therapy

Quick answer

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

This is an animal study, and the result is for the combination, not elamipretide alone.¹ Filipino readers should keep that finding tied to the cited study and verify any local product claim separately. That keeps the answer specific and easy to check.

What is SS-31, in plain language?

For readers following Elamipretide SS-31 Nicotinamide Mononucleotide NMN, the order matters: identify the study setting, read the result, then place the limitation beside it.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the source describes a focused result: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the population and method are part of the answer: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.¹

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the source also narrows the conclusion: this is an animal study, and the result is for the combination, not elamipretide alone.¹

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

A result becomes easier to trust when the Elamipretide SS-31 Nicotinamide Mononucleotide NMN details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the paper’s main result was that a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.²

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the study context keeps the conclusion precise: the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.²

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” that result does not erase its main limit: this was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.²

What does the wider evidence add?

The practical reading of Elamipretide SS-31 Nicotinamide Mononucleotide NMN is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the central finding was specific: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” that result came from this context: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.¹

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the finding should stop here: this is an animal study, and the result is for the combination, not elamipretide alone.¹

Which limits matter most?

The useful question in this Elamipretide SS-31 Nicotinamide Mononucleotide NMN story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the source describes a focused result: a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.²

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the population and method are part of the answer: the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.²

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the source also narrows the conclusion: this was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.²

How does the catalog identity fit?

For readers following Elamipretide SS-31 Nicotinamide Mononucleotide NMN, the order matters: identify the study setting, read the result, then place the limitation beside it.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the paper’s main result was that in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.³

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the study context keeps the conclusion precise: the 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.³

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” that result does not erase its main limit: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.³

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the study reported that in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁴ For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the main limit is equally important: the snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁴

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the central finding was specific: WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁵ For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the finding should stop here: appearance alone cannot authenticate a product or establish a research outcome.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

A result becomes easier to trust when the Elamipretide SS-31 Nicotinamide Mononucleotide NMN details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the central finding was specific: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.⁶

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” that result came from this context: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.⁶

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the finding should stop here: this is a description of its mechanism of action from regulatory and laboratory sources.⁶

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” researchers found that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁷ For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” one caution belongs beside that result: a portal record applies to the exact product or establishment named in that record.⁷

Bottom line

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the clearest reading is that in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

In the “Elamipretide SS-31 Nicotinamide Mononucleotide NMN” discussion, this was an open-label study with a small number of participants, and all knew they were receiving the active drug.³ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the cited source gives a focused answer: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” no single result settles the whole topic. This was an open-label study with a small number of participants, and all knew they were receiving the active drug.³ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

Within “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.² Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

For “Elamipretide SS-31 Nicotinamide Mononucleotide NMN,” in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.³ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this Elamipretide SS-31 Nicotinamide Mononucleotide NMN guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩²

5. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³

7. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

8. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩